MTE International - Blue Medical a Translumina Group company
Campobasso, Italy, 16th of August 2023. MTE International (www.mte-intl.com) is proud to announce a commercial partnership with BlueMedical a Translumina Group Company (https://www.wellinq.com/fabrication/protege-nc/) for the distribution of interventional cardiology breakthrough technologies in some Italian regions.
BlueMedical, established in 2013, manufactures balloon catheters, including drug-coated baloons (DCB) along with other speciality balloons for complex coronary interventions.
BlueMedical has developed Protégé NC and Protégé DCB catheters to better overcome current DCB technologies, as well as to provide high safety and efficacy. Protégé technology avoids any drug loss during the device advancement to lesion, helping to deliver a high drug concentration at the targeted site.
Campobasso, Italy, 1st of August 2022. MTE International (www.mte-intl.com) is proud to announce a commercial partnership with MC Health S.r.l (www.mchealth.it) for the distribution of interventional cardiology breakthrough technologies in Molise Region.
MC Health is the national distributor for OrbusNeich (www.orbusneich.com) of their range of innovative devices including an extensive portfolio of high-performance balloons (Sapphire family, Jade Family), speciality catheters (Scoreflex), microcatheters (Teleport and Teleport Control) and the orbital atherectomy system from C.S.I. (Diamondback 360 and Stealth 360) https://orbusneich.com/product/diamondback-360/ , https://orbusneich.com/product/stealth-360/
MTE International - MeMed
Campobasso, Italy, 1st of December 2021. MTE International (www.mte-intl.com) is proud to announce a commercial partnership with MeMed (www.memed.com) for the distribution in Italy of a breakthrough innovative technology: MeMed Covid-19 Severity™ on MeMed Key®.
MeMed COVID-19 Severity is a pioneering host-response technology that decodes signals of the immune system to accurately determine whether SARS-Cov-2 patients are likely to have a severe outcome. It does so by measuring multiple proteins from a serum sample and applying a machine-learning algorithm to stratify a patient's risk to experience a severe outcomes.
The test runs in 15 minutes on the company’s point-of-need platform, MeMed Key.®. The test aims to help physicians identify who may benefit from escalated care, and who can be safely discharged from hospital and to self-isolate at home. MeMed COVID-19 Severity™ has a CE Mark in Europe.
Campobasso, Italy, 30th of April 2021. MTE International (www.mte-intl.com) is proud to announce a commercial partnership with Translumina GmbH (www.translumina.com) for the distribution of interventional cardiology breakthrough technologies in Abruzzo, Marche, Molise & Umbria regions.
VIVO ISAR Stent: an innovative technology which eliminates the use of Polymer by using Dual Drug Technology: Sirolimus and Probucol.
10 years follow up clinical data of safety and efficacy in 3002 patients is published in Journal of American College of Cardiology. At 10 year clinical outcomes of stent thrombosis from RCTs in Patients with Coronary Artery Disease, VIVO ISAR demonstrated lower definite/ probable stent thrombosis rate than Xience (ISAR TEST-4) and Resolute.
Yukon Drug Eluting Stent is recommended by the latest European Society of Cardiology (ESC) guidelines for myocardial revascularization.
"Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease Results From the ISAR-TEST 4 Randomized Trial"
In this unique long term analysis at 10 years, Yukon has shown the lowest rate of Definite/ Probable Stent Thrombosis with a significant risk reduction than Cypher (50%) and numerically lower TLR rates as compared to Xience (29%) while maintaining the similar efficacy.